Cargando…
645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II
BACKGROUND: Commercially available enzyme immunoassays (EIAs) for detection of norovirus antigen have poor sensitivity and are limited to use in investigations of a gastroenteritis outbreak. Hence, there remains a need for a standalone high-sensitivity assay that enables rapid and accurate detection...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811303/ http://dx.doi.org/10.1093/ofid/ofz360.713 |
_version_ | 1783462450482380800 |
---|---|
author | Dave, Gipshu Katzenbach, Phoebe Sandlund, Johanna Estis, Joel Mukherjee, Ali Nolan, Niamh Almazan, Anna Hadass, Orr Noland, Brian Bishop, Jeffrey J Banaei, Niaz Riner, Diana K Todd, John |
author_facet | Dave, Gipshu Katzenbach, Phoebe Sandlund, Johanna Estis, Joel Mukherjee, Ali Nolan, Niamh Almazan, Anna Hadass, Orr Noland, Brian Bishop, Jeffrey J Banaei, Niaz Riner, Diana K Todd, John |
author_sort | Dave, Gipshu |
collection | PubMed |
description | BACKGROUND: Commercially available enzyme immunoassays (EIAs) for detection of norovirus antigen have poor sensitivity and are limited to use in investigations of a gastroenteritis outbreak. Hence, there remains a need for a standalone high-sensitivity assay that enables rapid and accurate detection of norovirus antigen. METHODS: The Singulex Clarity norovirus assay is currently in development for use on the Singulex Clarity(®) system (Singulex Inc., Alameda, CA, USA), a fully-automated platform powered by Single Molecule Counting technology (registered with the FDA and CE marked). The assay uses paramagnetic microparticles bound to capture antibody and a fluorescently labeled reporter antibody to detect virion capsid protein of norovirus genogroups I (GI) and II (GII) in the stool. For the development of Clarity Norovirus assay, diagnostic performance of 4 antibody pairs (as Capture and Detection reagent) were evaluated by testing 137 stool samples from patients with suspected norovirus infection. Samples were sourced from three providers: (1) 90 genotyped samples of which 75 were positive (19 different genotypes) and 15 were negative by the CDC assay, (2) 3 samples positive and 5 samples negative by the BioFire(®) FilmArray(®) Gastrointestinal Panel, and (3) 39 samples negative by a lab-developed test using Cepheid reagents (SmartCycler®). RESULTS: From all the antibody pairs tested, one of the pairs had best performance with the area under the receiver operating characteristic (AuROC) curve demonstrating a C-Statistic of 0.959 (95% CI 0.921–0.997), compared with AuROC C-statistic of 0.943 (95% CI 0.896–0.990), 0.871 (95% CI 0.807–0.936), and 0.914 (95% CI 0.863–0.964) for the three other pairs. The Clarity assay detected all 19 different genotypes tested (figures). CONCLUSION: The ultrasensitive and rapid Clarity norovirus assay (in development) for detection of GI and GII demonstrated excellent performance with one of the antibody pairs tested and detected all 19 tested genotypes. The Clarity assay may offer a standalone solution for norovirus diagnostics. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6811303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68113032019-10-29 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II Dave, Gipshu Katzenbach, Phoebe Sandlund, Johanna Estis, Joel Mukherjee, Ali Nolan, Niamh Almazan, Anna Hadass, Orr Noland, Brian Bishop, Jeffrey J Banaei, Niaz Riner, Diana K Todd, John Open Forum Infect Dis Abstracts BACKGROUND: Commercially available enzyme immunoassays (EIAs) for detection of norovirus antigen have poor sensitivity and are limited to use in investigations of a gastroenteritis outbreak. Hence, there remains a need for a standalone high-sensitivity assay that enables rapid and accurate detection of norovirus antigen. METHODS: The Singulex Clarity norovirus assay is currently in development for use on the Singulex Clarity(®) system (Singulex Inc., Alameda, CA, USA), a fully-automated platform powered by Single Molecule Counting technology (registered with the FDA and CE marked). The assay uses paramagnetic microparticles bound to capture antibody and a fluorescently labeled reporter antibody to detect virion capsid protein of norovirus genogroups I (GI) and II (GII) in the stool. For the development of Clarity Norovirus assay, diagnostic performance of 4 antibody pairs (as Capture and Detection reagent) were evaluated by testing 137 stool samples from patients with suspected norovirus infection. Samples were sourced from three providers: (1) 90 genotyped samples of which 75 were positive (19 different genotypes) and 15 were negative by the CDC assay, (2) 3 samples positive and 5 samples negative by the BioFire(®) FilmArray(®) Gastrointestinal Panel, and (3) 39 samples negative by a lab-developed test using Cepheid reagents (SmartCycler®). RESULTS: From all the antibody pairs tested, one of the pairs had best performance with the area under the receiver operating characteristic (AuROC) curve demonstrating a C-Statistic of 0.959 (95% CI 0.921–0.997), compared with AuROC C-statistic of 0.943 (95% CI 0.896–0.990), 0.871 (95% CI 0.807–0.936), and 0.914 (95% CI 0.863–0.964) for the three other pairs. The Clarity assay detected all 19 different genotypes tested (figures). CONCLUSION: The ultrasensitive and rapid Clarity norovirus assay (in development) for detection of GI and GII demonstrated excellent performance with one of the antibody pairs tested and detected all 19 tested genotypes. The Clarity assay may offer a standalone solution for norovirus diagnostics. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811303/ http://dx.doi.org/10.1093/ofid/ofz360.713 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Dave, Gipshu Katzenbach, Phoebe Sandlund, Johanna Estis, Joel Mukherjee, Ali Nolan, Niamh Almazan, Anna Hadass, Orr Noland, Brian Bishop, Jeffrey J Banaei, Niaz Riner, Diana K Todd, John 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II |
title | 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II |
title_full | 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II |
title_fullStr | 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II |
title_full_unstemmed | 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II |
title_short | 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II |
title_sort | 645. singulex clarity norovirus assay (in development) provides ultrasensitive detection of norovirus genogroups i and ii |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811303/ http://dx.doi.org/10.1093/ofid/ofz360.713 |
work_keys_str_mv | AT davegipshu 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT katzenbachphoebe 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT sandlundjohanna 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT estisjoel 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT mukherjeeali 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT nolanniamh 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT almazananna 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT hadassorr 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT nolandbrian 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT bishopjeffreyj 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT banaeiniaz 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT rinerdianak 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii AT toddjohn 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii |